{"protocolSection":{"identificationModule":{"nctId":"NCT05696847","orgStudyIdInfo":{"id":"17370"},"secondaryIdInfos":[{"id":"I8F-MC-GPHV","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity","officialTitle":"A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-02-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-01-16","type":"ACTUAL"},"completionDateStruct":{"date":"2025-01-16","type":"ACTUAL"},"studyFirstSubmitDate":"2023-01-17","studyFirstSubmitQcDate":"2023-01-17","studyFirstPostDateStruct":{"date":"2023-01-25","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-07-15","resultsFirstSubmitQcDate":"2025-08-22","resultsFirstPostDateStruct":{"date":"2025-08-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-22","lastUpdatePostDateStruct":{"date":"2025-08-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period."},"conditionsModule":{"conditions":["Obesity"],"keywords":["Pediatrics","Obesity","Chronic weight management"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":28,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1: Placebo (BW >=50 kg)","type":"PLACEBO_COMPARATOR","description":"Participants in this cohort had a screening body weight (BW) of at least 50 kilograms (kg) received placebo administered subcutaneously (SC) once weekly (QW) during Weeks 1 to 8.","interventionNames":["Drug: Placebo"]},{"label":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","type":"EXPERIMENTAL","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 milligrams (mg) tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8.","interventionNames":["Drug: Tirzepatide"]},{"label":"Cohort 2: Placebo (BW <50 kg)","type":"PLACEBO_COMPARATOR","description":"Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW during Weeks 1 to 8.","interventionNames":["Drug: Placebo"]},{"label":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","type":"EXPERIMENTAL","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8.","interventionNames":["Drug: Tirzepatide"]},{"label":"Cohort 3: Placebo (BW 40 to 60 kg)","type":"PLACEBO_COMPARATOR","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW during Weeks 1 to 8.","interventionNames":["Drug: Placebo"]},{"label":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","type":"EXPERIMENTAL","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8.","interventionNames":["Drug: Tirzepatide"]}],"interventions":[{"type":"DRUG","name":"Tirzepatide","description":"Administered SC","armGroupLabels":["Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)"],"otherNames":["LY3298176"]},{"type":"DRUG","name":"Placebo","description":"Administered SC","armGroupLabels":["Cohort 1: Placebo (BW >=50 kg)","Cohort 2: Placebo (BW <50 kg)","Cohort 3: Placebo (BW 40 to 60 kg)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)","description":"Percentage of participants with TEAEs and SAEs were reported here. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.","timeFrame":"Baseline through Week 14"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide","description":"PK: AUC0-tau of tirzepatide was reported.","timeFrame":"Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6."},{"measure":"PK: Maximum Concentration (Cmax) of Tirzepatide","description":"PK: Cmax of tirzepatide","timeFrame":"Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female participants with body mass index (BMI) ≥ the 95th percentile for age and sex\n* Have failed to achieve adequate weight loss through lifestyle modification in the investigator's opinion\n* Female participants only: Determined as prepubertal Tanner Stage 1.\n\nExclusion Criteria:\n\n* Change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records\n* Have obesity induced by other endocrinologic disorders (for example, Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity\n* Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis; or have other GI disorders\n* Have a known clinically significant gastric emptying, have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surger, or have endoscopic or device-based therapy for obesity or have had device removal within the last 6 months.\n* Have confirmed type 1 or type 2 diabetes mellitus\n* Have a history or current cerebrovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the IP; or may interfere with the interpretation of data","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Atlanta Center of Medical Research","city":"Atlanta","state":"Georgia","zip":"30331 2012","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Lynn Health Science Institute","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Baylor College of Medicine","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cohort 1: Placebo (BW >=50 kg)","description":"Participants in this cohort had a screening body weight (BW) of at least 50 kilograms (kg) received placebo administered subcutaneously (SC) once weekly (QW) during Weeks 1 to 8."},{"id":"FG001","title":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 milligrams (mg) tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."},{"id":"FG002","title":"Cohort 2: Placebo (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW during Weeks 1 to 8."},{"id":"FG003","title":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8."},{"id":"FG004","title":"Cohort 3: Placebo (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW during Weeks 1 to 8."},{"id":"FG005","title":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"7"}]},{"type":"Received At Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Withdrawal by Parent/Guardian","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who received at least one dose of study drug.","groups":[{"id":"BG000","title":"Cohort 1: Placebo (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received placebo administered SC QW during Weeks 1 to 8."},{"id":"BG001","title":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."},{"id":"BG002","title":"Cohort 2: Placebo (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW during Weeks 1 to 8."},{"id":"BG003","title":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8."},{"id":"BG004","title":"Cohort 3: Placebo (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW during Weeks 1 to 8."},{"id":"BG005","title":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"27"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"27"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"17"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"10"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"5"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"22"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"14"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"13"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"27"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)","description":"Percentage of participants with TEAEs and SAEs were reported here. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.","populationDescription":"All participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline through Week 14","groups":[{"id":"OG000","title":"Cohort 1: Placebo (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received placebo administered SC QW during Weeks 1 to 8."},{"id":"OG001","title":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."},{"id":"OG002","title":"Cohort 2: Placebo (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW during Weeks 1 to 8."},{"id":"OG003","title":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8."},{"id":"OG004","title":"Cohort 3: Placebo (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW during Weeks 1 to 8."},{"id":"OG005","title":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"7"}]}],"classes":[{"title":"TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"83.3"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"85.7"},{"groupId":"OG004","value":"33.3"},{"groupId":"OG005","value":"100.0"}]}]},{"title":"SAE","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of Tirzepatide","description":"PK: AUC0-tau of tirzepatide was reported.","populationDescription":"All participants who received at least one dose of tirzepatide and had evaluable PK data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram *hour per milliliter (ng*h/mL)","timeFrame":"Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.","groups":[{"id":"OG000","title":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."},{"id":"OG001","title":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8."},{"id":"OG002","title":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105000","spread":"33100"},{"groupId":"OG001","value":"80800","spread":"9580"},{"groupId":"OG002","value":"156000","spread":"22500"}]}]}]},{"type":"SECONDARY","title":"PK: Maximum Concentration (Cmax) of Tirzepatide","description":"PK: Cmax of tirzepatide","populationDescription":"All participants who received at least one dose of tirzepatide and had evaluable PK data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Predose on weeks 3, 6, 8; 12 and 24 hours post first dose; Within 24 to 96 hours post-dose at week 4; Within 120 to 168 hours post-dose at week 6.","groups":[{"id":"OG000","title":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."},{"id":"OG001","title":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 2.5 mg tirzepatide during Weeks 5 to 8."},{"id":"OG002","title":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW during Weeks 1 to 4 followed by 5 mg tirzepatide during Weeks 5 to 8."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"884","spread":"243"},{"groupId":"OG001","value":"674","spread":"63.8"},{"groupId":"OG002","value":"1280","spread":"194"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline Up To 14 Weeks","description":"All participants who received at least one dose of study drug. Per protocol, Adverse Event analysis was planned as per treatment regimen received.","eventGroups":[{"id":"EG000","title":"Cohort 1: Placebo (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kilograms (kg) received placebo administered subcutaneously (SC) once weekly (QW) in Weeks 1 to 8.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":0,"otherNumAtRisk":2},{"id":"EG001","title":"Cohort 1: 2.5-5 mg Tirzepatide (BW >=50 kg)","description":"Participants in this cohort had a screening body weight of at least 50 kg received 2.5 milligrams (mg) tirzepatide administered SC QW in Weeks 1 to 4 followed by 5 mg tirzepatide in Weeks 5 to 8.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6},{"id":"EG002","title":"Cohort 2: Placebo (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received placebo administered SC QW in Weeks 1 to 8.","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":0,"otherNumAtRisk":2},{"id":"EG003","title":"Cohort 2: 1.25-2.5 mg Tirzepatide (BW <50 kg)","description":"Participants in this cohort had a screening body weight less than 50 kg received 1.25 mg tirzepatide administered SC QW in Weeks 1 to 4 followed by 2.5 mg tirzepatide in Weeks 5 to 8.","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":6,"otherNumAtRisk":7},{"id":"EG004","title":"Cohort 3: Placebo (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received placebo administered SC QW in Weeks 1 to 8.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":1,"otherNumAtRisk":3},{"id":"EG005","title":"Cohort 3: 2.5-5 mg Tirzepatide (BW 40 to 60 kg)","description":"Participants in this cohort had a screening body weight between 40 to 60 kg, inclusive, received 2.5 mg tirzepatide administered SC QW in Weeks 1 to 4 followed by 5 mg tirzepatide in Weeks 5 to 8.","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":7,"otherNumAtRisk":7}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":5,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":9,"numAffected":4,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":7,"numAffected":3,"numAtRisk":7}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":7,"numAffected":5,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":11,"numAffected":6,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Solar dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":2},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-11-16","uploadDate":"2025-07-14T12:27","filename":"Prot_000.pdf","size":1010484},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-01-23","uploadDate":"2025-07-14T12:28","filename":"SAP_001.pdf","size":403229}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000098860","term":"Tirzepatide"}],"ancestors":[{"id":"D000067757","term":"Glucagon-Like Peptide-1 Receptor"},{"id":"D000067756","term":"Glucagon-Like Peptide Receptors"},{"id":"D043562","term":"Receptors, G-Protein-Coupled"},{"id":"D011956","term":"Receptors, Cell Surface"},{"id":"D008565","term":"Membrane Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D011964","term":"Receptors, Gastrointestinal Hormone"},{"id":"D018000","term":"Receptors, Peptide"}]}},"hasResults":true}